CONMED (CNMD) Stock Price, News & Analysis

Company Overview

CONMED Corporation (NYSE: CNMD) is a global medical technology company specializing in the development, manufacture and distribution of surgical devices and consumable products. With a focus on minimally invasive procedures, the company’s portfolio spans general surgery, orthopedics and endomechanics, providing solutions that enable surgeons to achieve precision and efficiency in the operating room. CONMED’s product offerings include advanced energy devices for tissue sealing and coagulation, suture passers, endoscopic instruments, arthroscopy shavers, fluid management systems and sterile processing equipment.

Founded in 1970 and headquartered in Largo, Florida, CONMED has grown through both organic innovation and strategic acquisitions. Over its history, the company has integrated complementary businesses to expand its technology platform, notably the acquisition of Linvatec in 2008, which broadened its reach in sports medicine and arthroscopy. This expansion has allowed CONMED to continuously refine its R&D capabilities, bringing new products to market that address evolving surgical needs and enhance patient outcomes.

CONMED serves a diversified customer base that includes hospitals, ambulatory surgery centers and specialty clinics across more than 70 countries. Its global footprint encompasses direct sales operations in North America, Europe and Asia-Pacific, supported by a network of independent distributors in emerging markets. By combining localized sales support with centralized manufacturing and quality assurance processes, the company maintains consistent product performance and regulatory compliance worldwide.

Leadership at CONMED is anchored by Chairman and Chief Executive Officer Keith H. Valentine, who has guided the company since 2003. Under his stewardship, CONMED has focused on driving operational efficiency, investing in new technologies and forging partnerships with clinicians to address unmet surgical needs. The company’s commitment to innovation is reflected in its annual investment programs and collaborative research initiatives, positioning it as a trusted partner for healthcare providers seeking advanced, reliable surgical solutions.

Key Stats

• Today's Range: $47.53 to $49.83
• 50-Day Range: $48.82 to $60.75
• 52-Week Range: $46.00 to $78.19
• Volume: 343,058 shs
• Average Volume: 447,719 shs
• Market Capitalization: $1.47 billion
• P/E Ratio: 12.52
• Dividend Yield: 1.68%
• Price Target: $62.20
• Consensus Rating: Hold

CONMED Stock Analysis - MarketRank™

CONMED scored higher than 95% of companies evaluated by MarketBeat, and ranked 140th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

CONMED has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

CONMED has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 16.55%

Earnings Growth

Earnings for CONMED are expected to grow by 16.55% in the coming year, from $4.35 to $5.07 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CONMED is 12.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.50.

Price to Earnings Ratio vs. Sector

The P/E ratio of CONMED is 12.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.08.

Price to Earnings Growth Ratio

CONMED has a PEG Ratio of 1.28. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

CONMED has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.57% of the float of CONMED has been sold short.

Short Interest Ratio / Days to Cover

CONMED has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in CONMED has recently decreased by 4.62%, indicating that investor sentiment is improving.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

CONMED pays a meaningful dividend of 1.60%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

CONMED does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of CONMED is 21.05%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, CONMED will have a dividend payout ratio of 15.78% next year. This indicates that CONMED will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -0.74

Percentage of Shares Shorted

7.57% of the float of CONMED has been sold short.

Short Interest Ratio / Days to Cover

CONMED has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in CONMED has recently decreased by 4.62%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.23

News Sentiment

CONMED has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for CONMED this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for CNMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CONMED insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $227,760.00 in company stock.

Percentage Held by Insiders

Only 3.10% of the stock of CONMED is held by insiders.

CNMD Stock Analysis - Frequently Asked Questions

How have CNMD shares performed this year?

CONMED's stock was trading at $68.44 at the beginning of the year. Since then, CNMD shares have decreased by 30.1% and is now trading at $47.8430.

How were CONMED's earnings last quarter?

CONMED Corporation (NYSE:CNMD) posted its quarterly earnings data on Wednesday, April, 30th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.81 by $0.14. The company's revenue was up 2.9% on a year-over-year basis.
Read the conference call transcript.

Who are CONMED's major shareholders?

Top institutional shareholders of CONMED include Mountain Pacific Investment Advisers LLC (0.45%), Confluence Investment Management LLC (0.42%), Pacific Capital Partners Ltd (0.20%) and Public Employees Retirement System of Ohio (0.14%). Insiders that own company stock include Charles Farkas, Daniel S Jonas, Pat Beyer, Brian Concannon, Curt R Hartman, Martha Goldberg Aronson, Peter K Shagory, Barbara J Schwarzentraub, Johonna Marie Pelletier, John D Ferrell, Stanley W Peters III, Richard Glaze and Todd W Garner.
View institutional ownership trends.

How do I buy shares of CONMED?

Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CONMED own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CONMED investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 4/30/2025
• Record date for 7/3 Dividend: 6/13/2025
• Ex-Dividend for 7/3 Dividend: 6/13/2025
• Dividend Payable: 7/03/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:CNMD
• CIK: 816956
• Web: www.conmed.com
• Phone: (727) 392-6464
• Fax: 315-797-0321
• Employees: 3,900
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CONMED: $62.20
• High Price Target: $80.00
• Low Price Target: $55.00
• Potential Upside/Downside: +26.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.80
• Trailing P/E Ratio: 12.96
• Forward P/E Ratio: 11.32
• P/E Growth: 1.28
• Net Income: $132.42 million
• Net Margins: 9.02%
• Pretax Margin: 11.04%
• Return on Equity: 14.36%
• Return on Assets: 5.86%

Debt

• Debt-to-Equity Ratio: 0.91
• Current Ratio: 2.26
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $1.31 billion
• Price / Sales: 1.17
• Cash Flow: $6.62 per share
• Price / Cash Flow: 7.44
• Book Value: $31.16 per share
• Price / Book: 1.58

Miscellaneous

• Outstanding Shares: 30,940,000
• Free Float: 29,981,000
• Market Cap: $1.52 billion
• Optionable: Optionable
• Beta: 1.20